BofA analyst Tazeen Ahmad raised the firm’s price target on Inozyme to $16 from $12 and keeps a Buy rating on the shares. The analyst is citing the company’s interim update on the ongoing phase 1/2 trials of INZ-701 in ENNP1 and ABCC6 deficiencies in adult patients, stating that the data provided further clinical validation to the durable effect of INZ-701 on serum PPi level normalization in ENPP1 patients over 18 months supported by further biomarker and clinical outcomes data. The update is seen positive as it shows signs of functional benefit to ENPP1 patients which correlate with positive biomarker data, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INZY:
- Inozyme announces data from trial of INZ-701 in adults with ABCC6 deficiency
- Inozyme announces data from trial of INZ-701 in adults with ENPP1 deficiency
- 3 Best Stocks to Buy Now, 9/13/2023, According to Top Analysts
- Inozyme reports inducement grants under Nasdaq listing rule
- Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference